PTC Therapeutics’ cash reaches $2.13 billion after product revenue surge in third quarter
Key Facts
PTC Therapeutics shares closed at $60.88 on November 2, 2026, according to EL7 data, while the report that the company approved a share buyback program on November 3 could not be confirmed from the announcement page or an available reliable source. It is therefore not possible to attribute an authorization on the matter to the board or to determine its value and terms. This places the closing price in the context of the stock’s trading before the date of the circulating report, without treating it as a reaction to an unverified announcement. The latest documented company information comes from its third-quarter results, announced on October 29. Those results provide a documented basis for assessing the company’s financial and operating performance in the preceding period.
The company reported total revenue of $357.807 million in the third quarter of 2026, compared with $211.007 million in the same period of 2025, according to the press release attached to its filing with the U.S. Securities and Exchange Commission. A significant part of this performance came from its commercial product portfolio: net product revenue was $275.9 million, versus $131.0 million a year earlier. The company said the year-over-year increase in product revenue exceeded 100%. These figures show an expansion in commercial revenue during the quarter, but do not establish that a decision was made to return capital to shareholders. The information that could be verified did not include independent confirmation of the program attributed to the company.
Sephience stood out among the revenue drivers, generating net revenue of $181.9 million in the third quarter of 2026, up 20% from the second quarter, according to the results statement. PTC said more than 2,000 patients were actively receiving the treatment worldwide as of September 30, 2026. These indicators offer a picture of the product’s growing market use during the period, alongside the broader annual increase in revenue from the commercial portfolio. Commenting on the results, Chief Executive Matthew Klein said the company was on track to achieve cash flow breakeven during this year, attributing this to Sephience’s momentum. This remains a management forecast reported by the company in its results, not confirmation that breakeven has already been achieved.
The company had $2.13 billion in cash, cash equivalents and marketable securities as of September 30, 2026, according to its quarterly report filed with the SEC. This figure reflects its cash and securities balance on that date and does not by itself establish that a share buyback program was approved or that any amount was allocated for that purpose. In its third-quarter results, PTC raised its 2026 total revenue guidance to a range of $1.29–1.32 billion. It also raised its product revenue guidance to $960–990 million, from the previous range of $850–950 million. The company thus links product growth with improved estimates for annual revenue, while any conclusion that it will use its liquidity for buybacks remains unconfirmed.
The company’s upcoming milestones include development programs mentioned in its results statement. It expected to complete the biologics license application submission for the ST-920 gene therapy for Fabry disease in the fourth quarter of 2026, with the possibility of accelerated approval and a commercial launch in 2027. It also said a Type C meeting with the U.S. Food and Drug Administration to discuss Phase 2 data for votoplam and a potential path to accelerated approval had been postponed to the first quarter of 2027 because of the agency’s scheduling. These timelines place the development program in the context of the company’s plans for the next two years, according to its stated forecasts. The report of a share buyback attributed to November 3, however, lacks reliable details in the available evidence that would allow it to be added to those plans.